Abstract
New treatments for metastatic melanoma work through distinct mechanisms: enhancing the immune response and blocking cellular proliferation. Agents that enhance the immune response include ipilimumab, pembrolizumb, and nivolumab; agents that block cellular proliferation include vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, and selumetinib. The translational impact of laboratory discoveries has revolutionized management of metastatic melanoma and enhanced the prognosis of affected patients.
Keywords:
immune therapy; metastatic melanoma; targeted therapy.
Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Azetidines / therapeutic use
-
Benzimidazoles / therapeutic use
-
Humans
-
Imidazoles / therapeutic use
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use*
-
Indoles / therapeutic use
-
Ipilimumab
-
Melanoma / drug therapy*
-
Melanoma / secondary
-
Molecular Targeted Therapy
-
Nivolumab
-
Oximes / therapeutic use
-
Piperidines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Pyridones / therapeutic use
-
Pyrimidinones / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Sulfonamides / therapeutic use
-
Vemurafenib
Substances
-
AZD 6244
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Azetidines
-
Benzimidazoles
-
Imidazoles
-
Immunologic Factors
-
Indoles
-
Ipilimumab
-
Oximes
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
Sulfonamides
-
binimetinib
-
Vemurafenib
-
Nivolumab
-
trametinib
-
pembrolizumab
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
cobimetinib
-
dabrafenib